The purpose of the study is to see if this combination medication is safe for the heart and blood vessels and whether it can help prevent serious heart-related problems. The study will look at how many people experience major heart events such as heart-related death, heart attack, or stroke. The study will also look at changes in body weight, blood pressure, cholesterol levels, and blood sugar control. For people with diabetes, the study will check their HbA1c, which is a measure of average blood sugar over time.

During the study, people will receive weekly injections for up to several months. The study will collect information about any side effects and will measure various health markers through blood tests and physical examinations. The study will also assess quality of life, sleep quality, and pain levels. For people with diabetes, the study will monitor for episodes of very low blood sugar. The study will track kidney function by measuring eGFRcr, which shows how well the kidneys are filtering waste from the blood, and will check protein levels in urine. The study will continue until enough information is gathered to determine whether the medication is effective and safe.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The purpose of the study is to compare the effects of BI 690517 to Spironolactone on kidney function and how blood flows through the kidneys. Researchers will look at Renal Hemodynamics, which refers to how blood moves through the kidney organs, and changes in protein levels in the blood and urine. The study will monitor how these treatments impact Glomerular Filtration Rate, a measurement used to check how well the kidneys filter waste from the blood, over a period of time.

During the study, participants will be observed at different intervals, specifically at 4 weeks and 26 weeks, to track changes in their kidney health and blood flow. Other substances such as Iohexol or Aminohippuric Acid may be used during certain procedures to help measure kidney performance.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

Participants in the study will receive either *carbachol* or *acetylcholine chloride* through a method called *intraocular instillation solution*, which involves applying the solution directly to the eye. The study will use a technique called *plethysmography* to measure blood flow. This method involves gently restricting blood flow in the arm to see how well the blood vessels work. The study aims to compare the effects of the two substances on blood flow.

The study will take place over a short period, with participants receiving the treatment and having their blood flow measured. The goal is to gather information on how these substances affect blood flow, which could help in understanding and treating *vascular dysfunction* in the future. Participants will not be informed about whether they are receiving *carbachol*, *acetylcholine chloride*, or a placebo during the study.

Participants in the study will receive either the active medications or a placebo. The trial will monitor the time it takes for participants to experience any major heart-related events, such as heart attacks, strokes, or the need for urgent heart procedures. The study will also track any serious side effects that may occur. The goal is to determine if adding low-dose colchicine or aspirin to standard diabetes care can reduce the risk of these heart-related issues.

The study will take place over a period of time, with regular follow-ups to assess the health of the participants. The results will help understand if these medications can provide additional protection against heart problems for people with Type 2 Diabetes who have not yet shown signs of heart disease.

The purpose of the study is to determine which of these two solutions is more effective and safe in protecting the heart during surgery. The study will look at how well each solution protects the heart by measuring certain markers in the blood that indicate heart injury, such as CK and Troponin T. It will also track the number of patients who survive the surgery and their hospital stay. The study will follow patients for a short period after their surgery to gather this information.

Participants in the study will receive either the Buckberg or Del Nido solution during their surgery. The study will monitor various aspects of their recovery, including the time it takes for their heart to start beating on its own again, the need for medications to support heart function, and any complications that may arise. The goal is to gather data that will help doctors choose the best method for protecting the heart during this type of surgery in the future.

The purpose of the study is to evaluate the long-term safety and effectiveness of Lerodalcibep in reducing cholesterol levels. Participants in the study will receive the drug once a month for a period of up to 72 weeks. The study aims to see how well the drug works in lowering cholesterol levels and to monitor any side effects that may occur over time. Patients involved in the study will continue their current cholesterol-lowering treatments while receiving the investigational drug.

Throughout the study, participants will have regular check-ups to assess their health and the impact of the treatment. This includes monitoring cholesterol levels and other health indicators to ensure the safety and effectiveness of the drug. The study is an extension of previous research and includes patients who have already participated in earlier phases of the trial. The goal is to provide additional information on how Lerodalcibep can help manage cholesterol levels in patients with high cardiovascular risk.

The purpose of the study is to assess whether using genetic information can help reduce muscle-related side effects that some people experience when taking statins. Participants will be randomly assigned to receive either a statin or a placebo, and their progress will be monitored over a period of nine months. During this time, researchers will track any muscle symptoms and changes in cholesterol levels, as well as any adjustments needed in the medication dosage.

The study will also evaluate the cost-effectiveness of using genetic testing to guide statin treatment. This means looking at whether the benefits of the genetic testing strategy outweigh the costs involved. Additionally, the study will explore new genetic markers that might predict how well patients respond to statins or whether they experience side effects. Participants will be asked to complete questionnaires about their adherence to the medication and any pain they experience, which will help researchers understand the overall impact of the treatment.

Participants in the study will receive esmolol, and their heart function will be monitored using a special type of heart imaging called echocardiography. This imaging technique helps doctors see how well the heart is working. The study aims to compare the results of echocardiography with and without esmolol to see if esmolol provides better information about the heart’s condition. The study will involve 1,000 patients who will be divided into different groups based on their specific health conditions.

Throughout the study, researchers will look at various heart function measurements and blood tests to understand how esmolol affects the heart. They will also assess whether esmolol can help predict future heart problems in patients with diabetes, cirrhosis, or those receiving cancer treatments. The study will help determine if esmolol can be a useful tool in diagnosing and managing heart issues in these patients.

During the study, participants will receive either protamine sulfate or the usual care after their TAVI procedure. The medication is given as an injection into a vein. The study will monitor participants from the time of the procedure until they are discharged from the hospital. Researchers will look at various outcomes, including the occurrence of any serious events like death, bleeding, or the need for a blood transfusion, to determine if protamine sulfate provides better results compared to the usual care.

The purpose of this study is to demonstrate whether systematic use of protamine sulfate can improve patient outcomes by reducing in-hospital mortality and complications related to the TAVI procedure. The study will continue until early 2026, with the goal of providing valuable insights into the potential benefits of protamine sulfate in this specific medical setting.

Participants in the study will receive either Milvexian, a placebo, or other medications such as Acetylsalicylic Acid (commonly known as aspirin) and Clopidogrel, which are standard treatments for preventing blood clots. Milvexian is taken as a film-coated tablet, and the study will compare its effectiveness and safety against these other treatments. The trial will be conducted over a period of several weeks, during which participants will be monitored for any occurrences of ischemic strokes or other related health events.

The purpose of this study is to explore new ways to prevent strokes and improve the safety and effectiveness of treatments for individuals at high risk of stroke. By participating in this trial, researchers hope to gather valuable information that could lead to better prevention strategies for stroke patients in the future.

Participants in the study will receive either Retatrutide or a placebo injection. The study will monitor changes in body weight and assess the overall health and safety of the participants throughout the trial. The goal is to understand how Retatrutide can help manage weight and improve health outcomes in people with these conditions.

The study will take place over a period of time, during which participants will receive regular injections and attend follow-up visits to track their progress. The information gathered from this study will contribute to understanding the potential benefits of Retatrutide for individuals with obesity and cardiovascular disease.

The condition being studied is detected through special heart imaging called Cardiovascular Magnetic Resonance imaging, which can show inflammation in the heart tissue. The treatment involves taking tablets of prednisolone and losartan by mouth for 16 weeks. Some participants will receive the actual medications, while others will receive placebo tablets that look the same but contain no active medication.

The study will measure how well the heart functions before and after treatment using detailed heart imaging. This will help determine if the combination of medications can reduce heart inflammation and improve heart function in people who have developed heart problems after COVID-19 infection. The treatment’s safety will also be monitored throughout the study period.